SE0101932D0 - Pharmaceutical combinations - Google Patents

Pharmaceutical combinations

Info

Publication number
SE0101932D0
SE0101932D0 SE0101932A SE0101932A SE0101932D0 SE 0101932 D0 SE0101932 D0 SE 0101932D0 SE 0101932 A SE0101932 A SE 0101932A SE 0101932 A SE0101932 A SE 0101932A SE 0101932 D0 SE0101932 D0 SE 0101932D0
Authority
SE
Sweden
Prior art keywords
pharmaceutical combinations
formula
pharmaceutically acceptable
acceptable derivative
combinations
Prior art date
Application number
SE0101932A
Other languages
English (en)
Swedish (sv)
Inventor
John Dixon
Robert Humphries
Alexander Nicol
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0101932A priority Critical patent/SE0101932D0/xx
Publication of SE0101932D0 publication Critical patent/SE0101932D0/xx
Priority to TW091110514A priority patent/TWI232751B/zh
Priority to ARP020101955A priority patent/AR034343A1/es
Priority to PL02366510A priority patent/PL366510A1/pl
Priority to MXPA03010761A priority patent/MXPA03010761A/es
Priority to BR0210034-7A priority patent/BR0210034A/pt
Priority to US10/479,019 priority patent/US20040146498A1/en
Priority to SK1473-2003A priority patent/SK14732003A3/sk
Priority to AU2002305952A priority patent/AU2002305952B2/en
Priority to PCT/SE2002/001033 priority patent/WO2002096428A1/en
Priority to CA002447648A priority patent/CA2447648A1/en
Priority to IL15878002A priority patent/IL158780A0/xx
Priority to CZ20033246A priority patent/CZ20033246A3/cs
Priority to HU0400069A priority patent/HUP0400069A3/hu
Priority to CNB028109120A priority patent/CN100352442C/zh
Priority to KR10-2003-7015565A priority patent/KR20040003029A/ko
Priority to JP2002592938A priority patent/JP2004532869A/ja
Priority to RU2003133216/15A priority patent/RU2331422C2/ru
Priority to EP02733751A priority patent/EP1397139A1/en
Priority to EEP200300589A priority patent/EE200300589A/xx
Priority to ZA200308780A priority patent/ZA200308780B/en
Priority to IS7051A priority patent/IS7051A/is
Priority to CO03105239A priority patent/CO5550445A2/es
Priority to NO20035315A priority patent/NO20035315D0/no
Priority to US11/406,746 priority patent/US20060189584A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0101932A 2001-05-31 2001-05-31 Pharmaceutical combinations SE0101932D0 (sv)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SE0101932A SE0101932D0 (sv) 2001-05-31 2001-05-31 Pharmaceutical combinations
TW091110514A TWI232751B (en) 2001-05-31 2002-05-20 Pharmaceutical combinations
ARP020101955A AR034343A1 (es) 2001-05-31 2002-05-24 Combinaciones farmaceuticas
EEP200300589A EE200300589A (et) 2001-05-31 2002-05-29 Ravimkoostised
CA002447648A CA2447648A1 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations
CNB028109120A CN100352442C (zh) 2001-05-31 2002-05-29 药物组合
BR0210034-7A BR0210034A (pt) 2001-05-31 2002-05-29 Conjunto de partes, método para tratamento de trombose, uso de um composto, formulação farmacêutica, uso e processo para preparação da mesma, e, composto
US10/479,019 US20040146498A1 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations
SK1473-2003A SK14732003A3 (sk) 2001-05-31 2002-05-29 Farmaceutická kompozícia obsahujúca antagonistu receptora P2T a ďalšie antitrombotické činidlo a jej použitie pri liečení trombózy
AU2002305952A AU2002305952B2 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations
PCT/SE2002/001033 WO2002096428A1 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations
PL02366510A PL366510A1 (pl) 2001-05-31 2002-05-29 Kombinacje farmaceutyczne
IL15878002A IL158780A0 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations comprising a p2t (p2y12) receptor antagonist and another anti-thrombotic agent and their use in the treatment and prevention of thrombosis
CZ20033246A CZ20033246A3 (cs) 2001-05-31 2002-05-29 Farmaceutická kompozice obsahující antagonistu receptoru P2T a další antitrombotické činidlo a její použití při léčení trombózy
HU0400069A HUP0400069A3 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations and their use in preventing and treating the thrombosis
MXPA03010761A MXPA03010761A (es) 2001-05-31 2002-05-29 Combinaciones farmaceuticas.
KR10-2003-7015565A KR20040003029A (ko) 2001-05-31 2002-05-29 약학 조합물
JP2002592938A JP2004532869A (ja) 2001-05-31 2002-05-29 医薬組成物
RU2003133216/15A RU2331422C2 (ru) 2001-05-31 2002-05-29 Фармацевтические комбинации
EP02733751A EP1397139A1 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations
ZA200308780A ZA200308780B (en) 2001-05-31 2003-11-11 Pharmaceutical combinations.
IS7051A IS7051A (is) 2001-05-31 2003-11-26 Lyfjasamsetningar
CO03105239A CO5550445A2 (es) 2001-05-31 2003-11-28 Combinaciones farmaceuticas
NO20035315A NO20035315D0 (no) 2001-05-31 2003-11-28 Farmasöytiske kombinasjoner
US11/406,746 US20060189584A1 (en) 2001-05-31 2006-04-17 Pharmaceutical combinations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101932A SE0101932D0 (sv) 2001-05-31 2001-05-31 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
SE0101932D0 true SE0101932D0 (sv) 2001-05-31

Family

ID=20284321

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0101932A SE0101932D0 (sv) 2001-05-31 2001-05-31 Pharmaceutical combinations

Country Status (24)

Country Link
US (2) US20040146498A1 (pl)
EP (1) EP1397139A1 (pl)
JP (1) JP2004532869A (pl)
KR (1) KR20040003029A (pl)
CN (1) CN100352442C (pl)
AR (1) AR034343A1 (pl)
AU (1) AU2002305952B2 (pl)
BR (1) BR0210034A (pl)
CA (1) CA2447648A1 (pl)
CO (1) CO5550445A2 (pl)
CZ (1) CZ20033246A3 (pl)
EE (1) EE200300589A (pl)
HU (1) HUP0400069A3 (pl)
IL (1) IL158780A0 (pl)
IS (1) IS7051A (pl)
MX (1) MXPA03010761A (pl)
NO (1) NO20035315D0 (pl)
PL (1) PL366510A1 (pl)
RU (1) RU2331422C2 (pl)
SE (1) SE0101932D0 (pl)
SK (1) SK14732003A3 (pl)
TW (1) TWI232751B (pl)
WO (1) WO2002096428A1 (pl)
ZA (1) ZA200308780B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
JP2004346067A (ja) * 2003-04-28 2004-12-09 Mitsubishi Pharma Corp 抗血栓薬の治療可能時間を延長するための薬剤
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
JP2007514647A (ja) 2003-10-21 2007-06-07 インスパイアー ファーマシューティカルズ，インコーポレイティド テトラヒドロ−フロ［３，４−ｄ］ジオキソール化合物並びに血小板凝集を阻害する組成物及び方法
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
US7504497B2 (en) 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
WO2006045756A1 (en) * 2004-10-25 2006-05-04 Boehringer Ingelheim International Gmbh Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
JP2010508350A (ja) 2006-10-31 2010-03-18 ヤンセン ファーマシューティカ エヌ．ベー． Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
CA2780153A1 (en) * 2009-11-09 2011-05-12 Alexion Pharmaceuticals, Inc. Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
CN104230936A (zh) * 2009-12-03 2014-12-24 阿斯利康(瑞典)有限公司 三唑并[4,5-d]嘧啶血小板聚集抑制剂的共晶体
WO2011076401A1 (de) 2009-12-23 2011-06-30 Holger Schankin Acetylsalicylsäure-haltige, im wesentlichen wasserfreie pharmazeutische zusammensetzungen
EP2633857B1 (en) 2009-12-23 2015-08-12 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor and acetylsalicylic acid
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
US9101642B2 (en) 2011-06-01 2015-08-11 Astrazeneca Ab Ticagrelor co-crystal
WO2014191321A1 (en) * 2013-05-29 2014-12-04 Ratiopharm Gmbh Solid pharmaceutical dosage form
CN104277039B (zh) * 2014-09-19 2016-06-01 广东东阳光药业有限公司 含有取代丁炔基的吡唑并哌啶酮类化合物及其组合物及用途
WO2016116942A1 (en) * 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
AU2016210973B2 (en) * 2015-01-27 2019-02-14 Astrazeneca Ab Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
CN106204544B (zh) * 2016-06-29 2019-04-05 南京中观软件技术有限公司 一种自动提取图像中标志点位置及轮廓的方法和系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
TW427996B (en) * 1995-07-11 2001-04-01 Astra Pharma Prod Novel triazolopyrimidines and their use as medicaments
TWI238827B (en) * 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
CN1346292A (zh) * 1999-03-11 2002-04-24 杜邦药品公司 凝血因子Xa抑制剂与阿司匹林、组织纤溶酶原激活物(TPA)、GPⅡb/Ⅲa拮抗剂、低分子量肝素或肝素联合用于治疗血栓形成
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations

Also Published As

Publication number Publication date
US20040146498A1 (en) 2004-07-29
RU2331422C2 (ru) 2008-08-20
TWI232751B (en) 2005-05-21
WO2002096428A1 (en) 2002-12-05
SK14732003A3 (sk) 2004-05-04
PL366510A1 (pl) 2005-02-07
HUP0400069A3 (en) 2006-02-28
US20060189584A1 (en) 2006-08-24
EP1397139A1 (en) 2004-03-17
CZ20033246A3 (cs) 2004-02-18
CO5550445A2 (es) 2005-08-31
HUP0400069A2 (hu) 2004-04-28
ZA200308780B (en) 2005-02-11
CN1512885A (zh) 2004-07-14
AU2002305952B2 (en) 2007-08-09
IL158780A0 (en) 2004-05-12
AR034343A1 (es) 2004-02-18
CA2447648A1 (en) 2002-12-05
NO20035315D0 (no) 2003-11-28
JP2004532869A (ja) 2004-10-28
MXPA03010761A (es) 2004-03-02
IS7051A (is) 2003-11-26
CN100352442C (zh) 2007-12-05
RU2003133216A (ru) 2005-04-20
BR0210034A (pt) 2004-08-10
KR20040003029A (ko) 2004-01-07
EE200300589A (et) 2004-02-16

Similar Documents

Publication Publication Date Title
SE0101932D0 (sv) Pharmaceutical combinations
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
ATE302775T1 (de) Carbolinderivate
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
DE602004024375D1 (de) Carboxamidderivate
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
SE0102315D0 (sv) Compounds
MXPA03006224A (es) Inhibidores de cruzipaina y otras proteasas de cisteina.
DE60121461D1 (de) Kondensierte pyridoindolderivate
ATE346067T1 (de) Carbolinderivate
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
BR0313385A (pt) Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz
DK1379508T3 (da) N-(aryl)-2arylethensulfonamider og terapeutiske anvendelser deraf
SE0102440D0 (sv) New compound
SE0102716D0 (sv) Novel compounds
SE0003476D0 (sv) Compounds
DE60112960D1 (de) Kondensierte pyridoindolderivate
MXPA04005809A (es) Inhibidores de proteinas quinasas.
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine